Nasdaq Most Active

Prism Marketview
  • Home
  • Indexes
    • All Indexes
    • Aerospace and Defense
    • AI Datacenter and Infrastructure
    • Biotech
    • Cannabis
    • Comms and Media
    • Consumer Products
    • Cybersecurity
    • Crypto Mining
    • EV
    • Fintech
    • Global Health
    • Healthcare
    • MedDevices
    • Mental Health
    • New Energy
    • NextGen Tech & AI
    • Oil & Gas
    • Pet Care
    • Pharmaceuticals
    • Precious Metals
    • Psychedelics
    • Semiconductors
    • Space
    • Sports
    • Weight Loss
    • Wellness
    • Women?s Health
  • Companies
  • Trending News
    • PRISM View
    • Biotech
    • Finance
    • Healthcare
    • Technology
    • Login
    • User Profile
    • Log Out
  • Home
  • Indexes
    • All Indexes
    • Aerospace and Defense
    • AI Datacenter and Infrastructure
    • Biotech
    • Cannabis
    • Comms and Media
    • Consumer Products
    • Cybersecurity
    • Crypto Mining
    • EV
    • Fintech
    • Global Health
    • Healthcare
    • MedDevices
    • Mental Health
    • New Energy
    • NextGen Tech & AI
    • Oil & Gas
    • Pet Care
    • Pharmaceuticals
    • Precious Metals
    • Psychedelics
    • Semiconductors
    • Space
    • Sports
    • Weight Loss
    • Wellness
    • Women?s Health
  • Companies
  • Trending News
    • PRISM View
    • Biotech
    • Finance
    • Healthcare
    • Technology
    • Login
    • User Profile
    • Log Out

Home Psychedelics

Tag: Psychedelics

October 07, 2026

Clearmind Urges FDA to Consider At-Home Pathways for Non-Hallucinogenic Psychedelic Therapies

Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens, announced on October 7, 2026 that it submitted recommendations to the U.S….

Technicians work with stainless-steel processing equipment inside a pharmaceutical manufacturing facility.
October 05, 2026

Psyence BioMed Partners With Benuvia to Build U.S. Ibogaine Manufacturing Pathway

Key Points Psyence BioMed’s Texas subsidiary, TIRC, signed a manufacturing agreement with Benuvia Operations for planned U.S. production of pharmaceutical-grade ibogaine API. Benuvia operates an…

Ibogaine capsules arranged beside green leaves, representing Psyence BioMed’s planned U.S. ibogaine drug development program.
September 28, 2026

Psyence BioMed Signs Binding Term Sheet for Exclusive U.S. Ibogaine License

Key Points  TIRC and PsyLabs aim to sign a definitive agreement by November 30, 2026. If they do not, the binding term sheet will lapse….

Healthcare professional discusses medication with a patient, representing Clearmind Medicine’s research into non-hallucinogenic psychedelic-derived treatments for alcohol use disorder.
September 17, 2026

Clearmind Medicine Presents Non-Hallucinogenic Psychedelic Research at FDA Hearing

Key Points Clearmind Medicine’s Chief of Global Impact, Mary-Elizabeth Gifford, testified at the FDA’s September 14 hearing on the potential future therapeutic use of psychedelic…

Conceptual image of a human head with a tablet and colorful patterns, representing psychedelic-based research into treatments for generalized anxiety disorder.
September 14, 2026

Definium’s DT120 Posts Positive Phase 3 Results in Generalized Anxiety Disorder

Key Points Definium Therapeutics said its Phase 3 Panorama trial met its main goal and all key secondary efficacy endpoints in adults with generalized anxiety…

Business professional holding a glowing award symbol, representing industry recognition and innovation in biotechnology and healthcare.
September 02, 2026

Compass Pathways Earns 2026 Fierce 50 Recognition as Psilocybin Program Advances

Key Points Compass Pathways was named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech, and Fierce Healthcare. The recognition highlights organizations and…

Person reviews a rising 2026 financial chart on a laptop, representing Numinus Wellness’ quarterly revenue growth and expanding practitioner-training business.
August 31, 2026

Numinus Wellness Reports 29% Quarterly Revenue Growth as Practitioner Training Accelerates

Key Points Q4 fiscal 2025 revenue increased 29% sequentially to C$2.33 million. Gross profit rose 63.5% from the prior quarter to C$1.42 million. Gross margin…

Colorful psychedelic profile of a human face, representing Definium Therapeutics’ investigational LSD-based DT120 therapy for generalized anxiety disorder.
August 12, 2026

Definium’s Single-Dose Psychedelic Therapy Shows Phase 3 Promise for Anxiety

Key Points Definium Therapeutics reported positive Phase 3 results for DT120, its investigational LSD-based treatment for generalized anxiety disorder, or GAD. A single DT120 dose…

July 30, 2026

MIRA Pharmaceuticals Completes Exploratory Toxicology Dosing for MIRA-55 and SKNY-1, Advancing Preclinical Programs Toward IND-Enabling Design

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a clinical-stage pharmaceutical company developing oral small-molecule therapeutics for neurologic, inflammatory, metabolic, and neuropsychiatric disorders, announced on July 30, 2026…

July 16, 2026

PRISM Mid-Day Movers: Psychedelics and EV are Today’s Leaders.

AtaiBeckley Inc. (NASDAQ: ATAI) is ripping higher today, up about 33% to 7.125, after Eli Lilly announced a deal to acquire the company. Lilly is…

July 16, 2026

AtaiBeckley Takes Center Stage as Psychedelic Pioneer

AtaiBeckley just had a breakout moment, with its share price soaring on news that Eli Lilly is in talks to buy the psychedelic drug developer….

June 25, 2026

PRISM Mid-Day Movers: NextGen Tech & AI and Psychedelics are Today’s Leaders.

BlackBerry Limited (NYSE: BB) is putting in a strong session today, with the stock up about 20% to 10.37 from a prior close of 8.62….

Posts pagination

Page 1 Page 2 Next page

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup

News

  • Latest
  • PRISM View
  • Biotech
  • Finance
  • Healthcare
  • Technology

Indexes

  • Aerospace & Defense
  • AI Datacenter and Infrastructure
  • Biotech
  • Cannabis
  • Comms and Media
  • Consumer Products
  • Crypto Mining
  • Cybersecurity
  • EV
  • Fintech
  • Global Health
  • Healthcare
  • MedDevices
  • Mental Health
  • New Energy
  • NextGen Tech & AI
  • Oil & Gas
  • Pet Care
  • Pharmaceuticals
  • Psychedelics
  • Semiconductors
  • Space
  • Sports
  • Weight Loss
  • Wellness
  • Women’s Health
  • Home
  • About Us
  • Contact Us

Copyright © 2026 PRISM MarketView. All rights reserved.

  • Terms & Conditions
  • Privacy Policy
  • Disclaimer